Supernus Pharmaceuticals SUPN Net product sales — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's net product sales — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's net product sales — total revenues?
- Supernus Pharmaceuticals (SUPN) reported net product sales — total revenues of $150.75M in Q1 2026.
- How has Supernus Pharmaceuticals's net product sales — total revenues changed year-over-year?
- Supernus Pharmaceuticals's net product sales — total revenues increased by 6.2% year-over-year, from $141.99M to $150.75M.
- What is the long-term trend for Supernus Pharmaceuticals's net product sales — total revenues?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's net product sales — total revenues has grown at a 2.5% compound annual growth rate (CAGR), from $567.5M to $626.54M.
- What does net product sales — total revenues mean?
- This metric represents the aggregate gross revenue generated from the sale of pharmaceutical products after accounting for returns, discounts, and rebates. It serves as a primary indicator of the company's commercial success and market penetration within its core neuroscience portfolio. Monitoring this figure helps investors assess the overall scale and growth trajectory of the company's therapeutic offerings.